Group chairs propose funding strategy to jump-start correlative studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.” 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login